文献速递主动脉外科

胸主动脉腔内修复对B型主动脉夹层长期生存的影响

The Impact of Thoracic Endovascular Aortic Repair on Long-Term Survival in Type B Aortic Dissection.
PubMed 文献 · Ann Thorac Surg · 2017-08-12

本研究基于Emory主动脉数据库2000至2016年398例急性B型主动脉夹层患者,比较复杂型行急性期TEVAR与无并发症型接受优化药物治疗或后期干预的结局。无并发症患者中45.9%最终仍需手术或腔内修复,5年和10年无干预生存率分别为50.4%和32.9%,提示单纯药物治疗长期预后不佳。

要点

  • 无并发症急性B型夹层单纯药物治疗后45.9%仍需后期干预。
  • 急性期TEVAR可能为复杂型和无并发症型患者带来生存获益。
  • 开放手术患者死亡率和肾衰竭发生率最高,急性期TEVAR卒中发生率最高。

核心结论

  • 无并发症急性B型主动脉夹层采用优化药物治疗会导致高比例后期外科干预和较差的长期生存。
  • 在首次住院期间行TEVAR可能提供生存优势,或可作为复杂型和无并发症型急性B型夹层的最佳治疗。

研究设计与样本

  • 回顾性队列研究,基于Emory主动脉数据库2000至2016年数据。
  • 共纳入398例急性B型主动脉夹层患者,平均年龄57±12岁。
  • 复杂型患者行急性期TEVAR(aTEVAR,n=80),无并发症患者接受优化药物治疗(n=318)。
  • 无并发症患者按最终治疗分为慢性期TEVAR(cTEVAR,n=87)、开放主动脉置换(n=59)和优化药物治疗(n=172)三个亚组。

主要发现

  • 无并发症组中146例(45.9%)优化药物治疗失败,在慢性期接受开放手术(n=59)或腔内修复(cTEVAR,n=87)。
  • 首次住院院内死亡率为5%,复杂型与无并发症急性B型夹层组间相当。
  • 需要干预的患者中,开放手术组死亡率和肾衰竭发生率最高(分别为16.9%,p<0.01和10.2%,p=0.05)。
  • 急性期TEVAR组卒中发生率最高(7.5%,p<0.01)。
  • 三组间轻瘫和截瘫发生率均低且相当。

临床怎么用

  • 对于无并发症急性B型主动脉夹层,应认识到单纯优化药物治疗后期干预率较高且长期生存不佳。
  • 在首次住院期间考虑TEVAR可能为复杂型和无并发症型急性B型夹层患者提供生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, optimal medical therapy is first-line therapy for uncomplicated acute type B aortic dissection (aTBAD) despite poor long-term outcomes. This study examines the impact of thoracic endovascular aortic repair (TEVAR) in the acute and chronic phases on short-term and long-term survival of patients presenting with aTBAD. METHODS: A review of the Emory aortic database from 2000 to 2016 identified 398 patients diagnosed with aTBAD. At index hospitalization, complicated patients underwent TEVAR (aTEVAR [thoracic endovascular aortic repair in the acute phase], n = 80) and uncomplicated patients received optimal medical therapy (n = 318). Uncomplicated patients were divided into subgroups based on final treatment: (1) TEVAR (cTEVAR [thoracic endovascular aortic repair in the chronic phase], n = 87); (2) open aortic replacement (n = 59); and (3) optimal medical therapy (n = 172). Kaplan-Meier curves assessed long-term mortality. RESULTS: The mean age of patients was 57 ± 12 years. In the uncomplicated group, 146 patients (45.9%) patients failed optimal medical therapy and underwent open repair (n = 59) or endovascular repair (cTEVAR, n = 87) repair in the chronic phase. Inhospital mortality was 5% and equivalent between complicated and uncomplicated aTBAD groups at index hospitalization. For patients requiring intervention, mortality and renal failure were highest for open patients (16.9%, p < 0.01, and 10.2%, p = 0.05, respectively), and stroke was highest among aTEVAR patients (7.5%, p < 0.01). The incidence of paraparesis and paraplegia was low and equivalent among the three groups. Despite a higher mortality risk at presentation, there was a trend toward improved long-term survival among complicated aTBAD patients (complicated 84.1% versus uncomplicated 58.9%, p = 0.17). Intervention-free survival at 5 and 10 years for all uncomplicated patients was 50.4% and 32.9%, respectively. CONCLUSIONS: The treatment of uncomplicated aTBAD with optimal medical therapy results in a high incidence of surgical intervention and poor long-term survival. At the index hospitalization, TEVAR may confer a survival advantage and serve as optimal therapy for complicated and uncomplicated aTBAD patients.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Lou X, Chen EP, Duwayri YM, et al. The Impact of Thoracic Endovascular Aortic Repair on Long-Term Survival in Type B Aortic Dissection. Ann Thorac Surg. 2017. PMID: 28811003. doi:10.1016/j.athoracsur.2017.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。